FMS vs. MRNA: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at FMS and MRNA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
FMS trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, MRNA is a standard domestic listing.
| Symbol | FMS | MRNA |
|---|---|---|
| Company Name | Fresenius Medical Care AG | Moderna, Inc. |
| Country | Germany | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 14.81 billion USD | 10.46 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | September 17, 1996 | December 7, 2018 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of FMS and MRNA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | FMS | MRNA |
|---|---|---|
| 5-Day Price Return | 1.10% | 0.75% |
| 13-Week Price Return | -19.55% | 1.89% |
| 26-Week Price Return | -3.46% | -15.76% |
| 52-Week Price Return | 26.43% | -70.11% |
| Month-to-Date Return | -3.30% | -9.03% |
| Year-to-Date Return | -2.60% | -35.33% |
| 10-Day Avg. Volume | 0.57M | 7.78M |
| 3-Month Avg. Volume | 0.54M | 9.92M |
| 3-Month Volatility | 21.47% | 54.60% |
| Beta | 0.61 | 2.05 |
Profitability
Return on Equity (TTM)
FMS
4.70%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
FMS’s Return on Equity of 4.70% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
MRNA
-27.46%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
MRNA has a negative Return on Equity of -27.46%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
FMS
3.36%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
FMS’s Net Profit Margin of 3.36% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
MRNA
-94.31%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
MRNA has a negative Net Profit Margin of -94.31%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
FMS
7.57%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
FMS’s Operating Profit Margin of 7.57% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
MRNA
-106.34%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
MRNA has a negative Operating Profit Margin of -106.34%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | FMS | MRNA |
|---|---|---|
| Return on Equity (TTM) | 4.70% | -27.46% |
| Return on Assets (TTM) | 2.02% | -21.24% |
| Net Profit Margin (TTM) | 3.36% | -94.31% |
| Operating Profit Margin (TTM) | 7.57% | -106.34% |
| Gross Profit Margin (TTM) | 24.67% | 68.32% |
Financial Strength
Current Ratio (MRQ)
FMS
1.44
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
FMS’s Current Ratio of 1.44 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
MRNA
3.93
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
MRNA’s Current Ratio of 3.93 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
FMS
0.83
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
FMS’s Debt-to-Equity Ratio of 0.83 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MRNA
0.01
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
MRNA’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
FMS
5.73
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
FMS’s Interest Coverage Ratio of 5.73 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
MRNA
--
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
Interest Coverage Ratio data for MRNA is currently unavailable.
Financial Strength at a Glance
| Symbol | FMS | MRNA |
|---|---|---|
| Current Ratio (MRQ) | 1.44 | 3.93 |
| Quick Ratio (MRQ) | 1.08 | 3.59 |
| Debt-to-Equity Ratio (MRQ) | 0.83 | 0.01 |
| Interest Coverage Ratio (TTM) | 5.73 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
FMS
3.35%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 3.35%, FMS offers a more attractive income stream than most of its peers in the Health Care Providers & Services industry, signaling a strong commitment to shareholder returns.
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
FMS
187.56%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
At 187.56%, FMS’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Health Care Providers & Services industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | FMS | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 3.35% | 0.00% |
| Dividend Payout Ratio (TTM) | 187.56% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
FMS
19.23
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
FMS’s P/E Ratio of 19.23 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
MRNA
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for MRNA is currently unavailable.
Price-to-Sales Ratio (TTM)
FMS
0.65
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
FMS’s P/S Ratio of 0.65 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
MRNA
3.39
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, MRNA’s P/S Ratio of 3.39 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
FMS
1.07
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
FMS’s P/B Ratio of 1.07 is in the lower quartile for the Health Care Providers & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
MRNA
1.14
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
MRNA’s P/B Ratio of 1.14 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | FMS | MRNA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 19.23 | -- |
| Price-to-Sales Ratio (TTM) | 0.65 | 3.39 |
| Price-to-Book Ratio (MRQ) | 1.07 | 1.14 |
| Price-to-Free Cash Flow Ratio (TTM) | 6.26 | 34.41 |